Focus on treatment of lung carcinoid tumor

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 1533-1537

  Noel Savina, Elise ^a   Descourt, Renaud ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Bronchopulmonary tumor; Carcinoid tumor; Neuroendocrine tumor; Treatment

Indexed keywords

BEVACIZUMAB; CEPEGINTERFERON ALPHA2B; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; OCTREOTIDE; PLACEBO; PLATINUM COMPLEX; SOMATOSTATIN RECEPTOR; STREPTOZOCIN; VASCULOTROPIN RECEPTOR;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOID; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TARGETING; HUMAN; LIVER METASTASIS; LOBECTOMY; LUNG CANCER; LUNG SMALL CELL CANCER; METASTASIS; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84887255473     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S32464     Document Type: Review

References (23)

1. Tsuta K, Raso MG, Kalhor N, Liu DD, Wistuba II, Moran CA. Histologic features of low- and intermediate-grade neuroendocrine carcinoma (typical and atypical carcinoid tumors) of the lung. Lung Cancer. 2011;71(1):34-41.
2. Morandi U, Casali C, Rossi G. Bronchial typical carcinoid tumors. Semin Thorac Cardiovasc Surg. 2006;18(3):191-198.
3. Travis. Pathology of lung cancer. Clin Chest Med; 2002:23-81.
4. Bouvier N, Zegerling V, Halley A. [Primitive metastasizing bronchial carcinoid with long survival]. Rev Mal Respir. 2007;24(1):63-68. French [with English abstract].
5. Iglesias M, Belda J, Baldó X, et al. [Bronchial carcinoid tumor: a retrospective analysis of 62 surgically treated cases]. Arch Bronconeumol. 2004;40(5):218-221.Spanish [abstract in English].
6. Ducrocq X, Thomas P, Massard G, et al. Operative risk and prognostic factors of typical bronchial carcinoid tumors. Ann Thorac Surg. 1998;65(5):1410-1414.
7. Bölükbas S, Schirren J. Parenchyma-sparing bronchial sleeve resections in trauma, benign and malign diseases. Thorac Cardiovasc Surg. 2010;58(1):32-37.
8. Aberg T, Blöndal T, Nõu E, Malmaeus J. The choice of operation for bronchial carcinoids. Ann Thorac Surg. 1981;32(1):19-22.
9. Machuca TN, Cardoso PF, Camargo SM. Surgical treatment of bronchial carcinoid tumors: a single-center experience. Lung Cancer. 2010;70(2):158-162.
10. García-Yuste M, Matilla JM, Cueto A, et al; Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung for the Spanish Society of Pneumonology and Thoracic Surgery (EMETNE-SEPAR). Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung. Eur J Cardiothorac Surg. 2007;31(2):192-197.
11. Brokx HA, Risse EK, Paul MA, et al. Initial bronchoscopic treatment for patients with intraluminal bronchial carcinoids. J Thorac Cardiovasc Surg. 2007;133(4):973-978.
12. Saji H, Tsuboi M, Matsubayashi J, et al. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy. Anticancer Drugs. 2010;21(1):89-93.
13. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG; Eastern Cooperative Oncology Group. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol. 2005;23(22): 4897-4904.
14. Pavel ME, Hainsworth JD, Baudin E, et al; RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005-2012.
15. Oberg K, Hellman P, Kwekkeboom D, Jelic S; ESMO Guidelines Working Group. Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v220-v222.
16. Filosso PL, Ruffini E, Oliaro A, Papalia E, Donati G, Rena O. Long-term survival of atypical bronchial carcinoids with liver metastasis, treated with octreotide. Eur J Cardiothorac Surg. 2002;21(5):913-197.
17. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med. 2002;43(5):610-616.
18. Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, et al. 90Y-endotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010;28(10):1652-1659.
19. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26(20): 3403-3410.
20. Kölby L, Persson G, Franzén S, Ahrén B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg. 2003;90(6):687-693.
21. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008;26(8):1316-1323.
22. Rickman OB, Vohra PK, Sanyal B, et al. Analysis of ErbB receptors in pulmonary carcinoid tumors. Clin Cancer Res. 2009;15(10): 3315-3324.
23. Diaco DS, Hajarizadeh H, Mueller CR, Fletcher WS, Pommier RF, Woltering EA. Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization. Am J Surg. 1995;169(5): 523-528.